372 related articles for article (PubMed ID: 15769273)
1. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
2. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
3. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
4. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
5. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
Stockfleth E; Trefzer U; Garcia-Bartels C; Wegner T; Schmook T; Sterry W
Br J Dermatol; 2003 Nov; 149 Suppl 66():53-6. PubMed ID: 14616352
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
Gilliet M; Conrad C; Geiges M; Cozzio A; Thürlimann W; Burg G; Nestle FO; Dummer R
Arch Dermatol; 2004 Dec; 140(12):1490-5. PubMed ID: 15611427
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
[TBL] [Abstract][Full Text] [Related]
8. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
Wolf IH; Kodama K; Cerroni L; Kerl H
Am J Dermatopathol; 2007 Jun; 29(3):237-41. PubMed ID: 17519620
[TBL] [Abstract][Full Text] [Related]
9. Type I interferon-associated cytotoxic inflammation in lichen planus.
Wenzel J; Scheler M; Proelss J; Bieber T; Tüting T
J Cutan Pathol; 2006 Oct; 33(10):672-8. PubMed ID: 17026519
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
[TBL] [Abstract][Full Text] [Related]
11. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
12. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis.
Wenzel J; Schmidt R; Proelss J; Zahn S; Bieber T; Tüting T
Clin Exp Dermatol; 2006 Jul; 31(4):576-82. PubMed ID: 16716166
[TBL] [Abstract][Full Text] [Related]
13. Viral and nonviral uses of imiquimod: a review.
Gupta AK; Cherman AM; Tyring SK
J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314
[TBL] [Abstract][Full Text] [Related]
14. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus.
Wenzel J; Proelss J; Wiechert A; Zahn S; Bieber T; Tüting T
J Am Acad Dermatol; 2007 Apr; 56(4):648-50. PubMed ID: 17367614
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
16. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod: a review.
Gupta AK; Browne M; Bluhm R
J Cutan Med Surg; 2002; 6(6):554-60. PubMed ID: 12362256
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and other potential roles of an immune response modifier.
Gaspari AA
Cutis; 2007 Apr; 79(4 Suppl):36-45. PubMed ID: 17508494
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
20. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
